Slava Akmaev, BERG’s SVP & Chief Analytics Officer, is featured in this article that highlights how BERG is revolutionizing the research and development framework of therapeutic drugs through their AI platform for target discovery, identification of biomarkers, and drug repurposing. To read the full article, click here.

The aim of BERG’s approach is to identify potential treatments on the basis of the precise biological causes of disease. “We are turning the drug-discovery paradigm upside down by using patient-driven biology and data to derive more predictive hypotheses, rather than the traditional trial-and-error approach,” says Niven R. Narain, BERG’s co-founder and CEO. This Nature…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BERG’s BPM 31510 (ubidecarenone), a treatment candidate for patients with epidermolysis bullosa (EB), the company announced. This article goes on to discuss BERG’s commitment to the EB community and advancing much needed treatment options, while helping connect to the clinical trials for…

President and CEO Niven R. Narain discusses how BERG will use its bAIcis® platform to help AstraZeneca “home in on promising biological targets and possible agents against neurological diseases such as Parkinson’s.” Read the entire article: http://fortune.com/2018/03/19/big-pharma-ai-drugs-medicine

In an article that appeared on the “NBC News Mach” website, BERG President and CEO Niven R. Narain spoke about how artificial intelligence (AI) could be a potential “game-changer” in the development of personalized flu vaccines. Read the full article: https://www.nbcnews.com/mach/science/ai-helping-turn-tide-against-flu-two-important-ways-ncna840746

Speaking with CNN host Maggie Lake, Berg CEO Niven R. Narain discusses the severe impact of the flu this season, and how BERG will help partner Sanofi make its flu vaccines more effective. Watch the interview.